Durgical
EN
Open the app

Cytokine storm: CRS, HLH, sepsis and severe COVID-19

  • Topic

In a cytokine storm the immune system releases so many inflammatory signals that the response itself, not the trigger, causes shock and organ failure.

Updated

What it is

Cytokine storm is a life-threatening state of uncontrolled, systemic release of inflammatory cytokines such as IL-6, IL-1, TNF and IFN-γ. It shows as high fever, low blood pressure, capillary leak, cytopenias and multiorgan dysfunction. It occurs after CAR-T and T-cell-engaging therapies (cytokine release syndrome), in haemophagocytic lymphohistiocytosis, in severe infections including sepsis and COVID-19, and with superantigens. Treatment targets both the trigger and the dominant cytokine.

Key facts

  • Ferritin rises very high in HLH and macrophage activation syndrome, higher than in most other inflammatory states.
  • Soluble CD25 (IL-2 receptor α) is a marker of T-cell activation used in HLH work-up.
  • Corticosteroids broadly suppress cytokine production but increase infection risk.

Step by step

  1. A trigger activates many cells at once: CAR-T or bispecific-engaged T cells, a virus, a superantigen, or killer cells that cannot finish their job.
  2. Activated T and NK cells release IFN-γ; macrophages respond with IL-6, IL-1 and TNF.
  3. These cytokines activate yet more macrophages and T cells: the loop feeds itself.
  4. Endothelium is activated and leaky: fever, hypotension, oedema and hypoxaemia.
  5. Macrophages engulf blood cells and the liver is injured: cytopenias, very high ferritin, low fibrinogen.
  6. Without treatment the result is multiorgan failure; blocking the dominant cytokine and removing the trigger breaks the loop.

Main settings of cytokine storm

SettingTriggerDominant mediatorsCluesTargeted approach
Cytokine release syndromeCAR-T cells, bispecific T-cell engagersIL-6, IFN-γFever and hypotension days after infusion; may come with neurotoxicityTocilizumab, glucocorticoids
Haemophagocytic lymphohistiocytosis (HLH)Inherited cytotoxicity defects; EBV, cancer, autoimmune diseaseIFN-γ, IL-18Fever, splenomegaly, cytopenias, very high ferritin, low fibrinogenEtoposide-based therapy, anti-IFN-γ, transplant for genetic forms
Macrophage activation syndromeStill disease, systemic juvenile arthritis, lupusIL-1, IL-18, IFN-γFalling ESR with rising ferritin in a known rheumatic patientIL-1 blockade, glucocorticoids
SepsisBacterial infectionTNF, IL-1, IL-6Organ dysfunction from infection; later immune paralysisAntibiotics and source control; supportive care
Severe COVID-19SARS-CoV-2IL-6, IL-1, type I interferon imbalanceHypoxaemia, high CRP and D-dimer, lymphopeniaDexamethasone, tocilizumab or JAK inhibitor
Toxic shock syndromeStaphylococcal or streptococcal superantigensIL-2, TNF, IFN-γ from many T cellsFever, rash, desquamation, shockRemove source, antibiotics, supportive care

Clinical notes

  • Cytokine release syndrome is graded by fever, hypotension and oxygen needs; neurotoxicity (ICANS) is assessed separately.
  • In a febrile patient with cytopenias and splenomegaly, very high ferritin should prompt consideration of HLH.
  • Dexamethasone reduced mortality in hospitalised COVID-19 patients who needed oxygen.

Common traps

  • Cytokine release syndrome after CAR-T means the therapy failed: CRS reflects T-cell activation and often accompanies a working therapy.
  • Tocilizumab blocks IL-6 itself: it blocks the IL-6 receptor, so serum IL-6 can rise after it is given.
  • A falling ESR in a sick rheumatic patient means improvement: in macrophage activation syndrome fibrinogen is consumed, so ESR falls while ferritin soars.
  • HLH is always inherited: secondary HLH from EBV, cancer or autoimmune disease is more common in adults than the familial form.
  • Glucocorticoids are harmless add-ons in every storm: they help in CRS and severe COVID-19 but increase infection risk, so sepsis care relies on source control.

Test yourself

Think of the answer, then tap the question to see it.

Five days after CAR-T infusion a patient has fever and hypotension. Which cytokine pathway is targeted first, and how?

IL-6, with tocilizumab blocking the IL-6 receptor; glucocorticoids are added for severe or neurologic toxicity.

A febrile patient has splenomegaly, pancytopenia, very high ferritin and low fibrinogen. What should you suspect and why the fibrinogen?

HLH: activated macrophages and liver injury consume and fail to make fibrinogen, while IFN-γ-driven macrophages raise ferritin.

Why does toxic shock syndrome cause a storm without any prior immunity?

Superantigens bind MHC class II and the TCR Vβ outside the antigen groove, activating a large fraction of all T cells at once.

Add to my cards (3)

Elsewhere in DurgiPedia

Connections

← All of immunology

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers (National Cancer Institute (NIH), 2024); Familial hemophagocytic lymphohistiocytosis (MedlinePlus Genetics, US National Library of Medicine, 2024); COVID-19 (Coronavirus Disease 2019) (MedlinePlus, US National Library of Medicine, 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.